UK's First Commercial Synthetic Biology Foundry Goes Into Production
News Apr 06, 2016
SynbiCITE has opened the country’s first commercial synthetic biology foundry. SynbiCITE’s Foundry provides automated end-to-end design, construction and validation of synthetic biologic components combined with a unique open-access and sharing software which allows researchers to speed-up innovation by sharing their biodesign protocols with different labs around the world.
Dr Stephen Chambers, CEO, describes the Foundry’s mission: “To accelerate the translation of synthetic biology R&D into the marketplace. The Foundry has been created and built to operate as a ‘cloud lab’ to support synthetic biologists across the UK and is for everyone in the business of synthetic biology and who can use synthetic biology – the engineering of biology - in their business. These remote users send their biodesigns to the Foundry, which executes the work and delivers the data or prototype to the biodesigner once the work is complete. The Foundry provides a ‘maker space’ for entrepreneurial scientists looking to commercialize their research, ready access to state-of-the-art automation for SMEs, and is a facility for large and small companies to explore the enormous potential of synthetic biology.”
The Foundry will enable automated manufacturing processes that meets industry requirements for using applications of synthetic biology in life sciences and many other industry sectors including fine and special chemicals, energy, agriculture and waste remediation. It will take biodesign towards growing the global bioeconomy.
Staphylococcus epidermidis is an ubiquitous colonizer of healthy human skin, but it is also a notorious source of serious nosocomial infections. Now, a new machine learning technique will help predict the risk of developing a serious, and possibly life-threatening S. epidermidis infection.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019